Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PDXK | O00764 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyritinol SCHEMBL30029763 | 1.00 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL27694054 | 0.98 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL27894712 | 0.98 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL1171682 | 0.98 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL28859426 | 0.98 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL1305284 | 0.98 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL27694053 | 0.98 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL31418900 | 0.97 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL1171524 | 0.97 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| Pyritinol SCHEMBL27676156 | 0.97 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041812-B | Vulcanized neoprene capable of being repeatedly processed and preparation method thereof | 安徽忠德输送工程技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20250302964-A1 | Topical Compositions and Methods for Treatment of Diabetic Neuropathies | CROSS III WILLIAM H (US) | 2025-10-02 | — | — | US | claimed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| CN-120138199-A | Detection kit and detection method for rapidly detecting colletotrichum pyriformis | 华中农业大学 | 2025-06-13 | — | — | CN | claimed |
| EP-4212599-B1 | SELF-HEALING CERAMIC COATING AND PROCESS FOR FORMATION THEREOF | ILLINOIS TOOL WORKS (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2024079645-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | SINTALICA S.R.L. (IT) | 2024-04-18 | — | — | WO | claimed |
| US-20230381195-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI) AND RELATED DISORDERS | MEHRA AKHIL (US) | 2023-11-30 | — | — | US | claimed |
| CN-116999552-A | Composition containing auranofin and polysulfide and application thereof | 中山大学 | 2023-11-07 | — | — | CN | claimed |
| US-20230349891-A1 | RELEASABLE REAGENTS FOR CELL SEPARATION | Miltenyi Biotec B.V. & Co. KG (DE) | 2023-11-02 | — | — | US | claimed |
| US-20230310461-A1 | Compositions and Methods for Treatment of Prediabetes | CROSS III WILLIAM H (US) | 2023-10-05 | — | — | US | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| CN-1170346-A | Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process | WARNER LAMBERT CO (US) | 1998-01-14 | — | — | CN | claimed |
| WO-1997037629-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | claimed |
| EP-0797424-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-01 | — | — | EP | claimed |
| EP-0728005-A1 | METHYLENE BLUE FOR THE TREATMENT OR PROPHYLAXIS OF ANCEPHALOPATHY CAUSED BY IFOSFAMIDE | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-08-28 | — | — | EP | claimed |
| WO-1996018370-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1996-06-20 | — | — | WO | claimed |
| WO-1995013079-A1 | METHYLENE BLUE FOR THE TREATMENT OR PROPHYLAXIS OF ANCEPHALOPATHY CAUSED BY IFOSFAMIDE | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-05-18 | — | — | WO | claimed |
| US-5051410-A | Neurological degeneative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-09-24 | — | — | US | claimed |
| EP-0435886-A1 | ENHANCEMENT OF RELEASE OF NEUROTRANSMITTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-07-10 | — | — | EP | claimed |
| WO-1990002554-A1 | ENHANCEMENT OF RELEASE OF NEUROTRANSMITTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-03-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310461-A1 | Compositions and Methods for Treatment of Prediabetes | GPX1, GPX4, NFE2L2 | KDM4E 4445/4885ALDH1A1 320/4885HPGD 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.